Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Mesenchymal Stem Cells01:19

Mesenchymal Stem Cells

5.4K
Mesenchymal stem cells (MSCs) are adult stem cells that can differentiate into most connective tissue cell types, except for hematopoietic cells, depending upon the source of MSCs. For example, bone-marrow-derived MSCs (BM-MSCs) can differentiate into osteocytes, hepatocytes, and pancreatic and neuronal cells. MSCs can be isolated from various sources such as bone marrow, placenta, adipose tissue, teeth, and Wharton’s jelly, a gelatinous substance in the umbilical cord. The ease of their...
5.4K

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Risk Factors of Postoperative Acute Heart Failure in Elderly Patients After Hip Fracture Surgery.

Cureus·2024
Same author

Vepoloxamer improves functional recovery in rat after traumatic brain injury: A dose-response and therapeutic window study.

Neurochemistry international·2023
Same author

Mesenchymal stem cell-derived extracellular vesicles as a cell-free therapy for traumatic brain injury via neuroprotection and neurorestoration.

Neural regeneration research·2023
Same author

Therapeutic Role of microRNAs of Small Extracellular Vesicles from Human Mesenchymal Stromal/Stem Cells in Treatment of Experimental Traumatic Brain Injury.

Journal of neurotrauma·2022
Same author

MiR-17-92 Cluster-Enriched Exosomes Derived from Human Bone Marrow Mesenchymal Stromal Cells Improve Tissue and Functional Recovery in Rats after Traumatic Brain Injury.

Journal of neurotrauma·2021
Same author

Randomized controlled trial of Cerebrolysin's effects on long-term histological outcomes and functional recovery in rats with moderate closed head injury.

Journal of neurosurgery·2019

Related Experiment Video

Updated: Dec 20, 2025

Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
09:48

Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture

Published on: July 26, 2022

4.9K

Mesenchymal Stem Cell-Derived Exosomes Improve Functional Recovery in Rats After Traumatic Brain Injury: A

Yanlu Zhang1, Yi Zhang1, Michael Chopp1,2

  • 1Henry Ford Hospital, Detroit, MI, USA.

Neurorehabilitation and Neural Repair
|May 29, 2020
PubMed
Summary

Mesenchymal stem cell (MSC)-derived exosome therapy shows significant potential for treating traumatic brain injury (TBI). Treatment improved neurological function and reduced brain damage, with a wide therapeutic window up to 7 days post-injury.

Keywords:
cell therapyexosomesfunctional outcomeneuroinflammationneurovascular remodelingrattraumatic brain injury

More Related Videos

Tracking Superparamagnetic Iron Oxide-labeled Mesenchymal Stem Cells using MRI after Intranasal Delivery in a Traumatic Brain Injury Murine Model
10:03

Tracking Superparamagnetic Iron Oxide-labeled Mesenchymal Stem Cells using MRI after Intranasal Delivery in a Traumatic Brain Injury Murine Model

Published on: November 21, 2019

8.1K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.3K

Related Experiment Videos

Last Updated: Dec 20, 2025

Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture
09:48

Large-Scale Preparation of Synovial Fluid Mesenchymal Stem Cell-Derived Exosomes by 3D Bioreactor Culture

Published on: July 26, 2022

4.9K
Tracking Superparamagnetic Iron Oxide-labeled Mesenchymal Stem Cells using MRI after Intranasal Delivery in a Traumatic Brain Injury Murine Model
10:03

Tracking Superparamagnetic Iron Oxide-labeled Mesenchymal Stem Cells using MRI after Intranasal Delivery in a Traumatic Brain Injury Murine Model

Published on: November 21, 2019

8.1K
Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice
08:13

Purification and Transplantation of Myogenic Progenitor Cell Derived Exosomes to Improve Cardiac Function in Duchenne Muscular Dystrophic Mice

Published on: April 10, 2019

6.3K

Area of Science:

  • Neuroscience
  • Regenerative Medicine
  • Cell Biology

Background:

  • Mesenchymal stem cell (MSC)-derived exosomes are crucial in regenerative medicine.
  • Traumatic brain injury (TBI) requires effective therapeutic interventions.

Purpose of the Study:

  • To evaluate the dose- and time-dependent efficacy of exosome treatment for TBI.
  • To determine the optimal therapeutic window for exosome administration post-TBI.

Main Methods:

  • Male rats with induced TBI received varying doses of exosomes (50, 100, 200 µg) or vehicle intravenously.
  • Therapeutic window assessed by initiating 100 µg exosome treatment at 1, 4, or 7 days post-TBI.
  • Neurological function, spatial learning, neuronal loss, angiogenesis, neurogenesis, and neuroinflammation were evaluated over 5 weeks.

Main Results:

  • Exosome treatment significantly improved sensorimotor and cognitive functions compared to vehicle.
  • A dose of 100 µg/rat showed superior therapeutic effects.
  • Treatment initiated at 1 day post-TBI yielded better outcomes than delayed treatments (4 or 7 days).
  • Exosomes reduced neuronal cell loss, promoted angiogenesis and neurogenesis, and decreased neuroinflammation.

Conclusions:

  • Exosomes demonstrate a broad effective dose range for TBI treatment.
  • A therapeutic window of at least 7 days post-TBI is established for exosome therapy.
  • Exosomes represent a promising novel therapeutic strategy for managing TBI.